Abstract Treatment of migraine is on the cusp of a new era with the development of drugs
that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its …

The occurrence of the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-
2), responsible for coronavirus disease 2019 (COVD-19), represents a catastrophic threat to …

Migraine is a common neurological disorder that afflicts up to 15% of the adult population in
most countries, with predominance in females. It is characterized by episodic, often disabling …

A novel human coronavirus prompted considerable worry at the end of the year 2019. Now,
it represents a significant global health and economic burden. The newly emerged …

Background Monoclonal antibodies (mAbs) towards CGRP or the CGRP receptor show
good prophylactic antimigraine efficacy. However, their site of action is still elusive. Due to …

Targeting receptor proteins, such as ligand-gated ion channels and G protein-coupled
receptors, has directly enabled the discovery of most drugs developed to modulate receptor …

Ethnopharmacological relevance Migraines have become a major threat to human health,
as they significantly affect human health and quality of life due to a high prevalence rate …

Adrenomedullin (AM) and calcitonin gene-related peptide (CGRP) receptors are critically
important for metabolism, vascular tone, and inflammatory response. AM receptors are also …

Calcitonin gene-related peptide (CGRP) has 37 amino acids. Initially, CGRP had
vasodilatory and nociceptive effects. As research progressed, evidence revealed that the …

Calcitonin gene‐related peptide (CGRP) is a neuropeptide produced by sensory nerves and
functions as a pain sensor. It acts by binding to the calcitonin‐like receptor (CLR, protein; …